A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

@inproceedings{Becher2017API,
  title={A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors},
  author={Oren J. Becher and Nathan E Millard and Shakeel Modak and Brian H. Kushner and S. M. S. Sirajul Haque and Ivan Spasojevi{\'c} and Tanya M. Trippett and Stephen W. Gilheeney and Yasmin N Khakoo and David Lyden and Kevin C De Braganca and Jill Marie Kolesar and Jason T Huse and Kim Kramer and Nai-Kong V Cheung and Ira J Dunkel},
  booktitle={PloS one},
  year={2017}
}
The PI3K/Akt/mTOR signaling pathway is aberrantly activated in various pediatric tumors. We conducted a phase I study of the Akt inhibitor perifosine in patients with recurrent/refractory pediatric CNS and solid tumors. This was a standard 3+3 open-label dose-escalation study to assess pharmacokinetics, describe toxicities, and identify the MTD for single… CONTINUE READING